Nexo Therapeutics
John Athanasopoulos is currently serving as the Vice President of Operations at nexo therapeutics. Prior to their current role, John held various leadership positions at Proteovant Therapeutics, Jnana Therapeutics, C4 Therapeutics, Inc., Broad Institute, Merck & Co., Inc., NeoGenesis Pharmaceuticals, Harvard Medical School, and Harvard University. John holds an MBA in Finance and Entrepreneurship from NYU Stern School of Business and a BS in Chemistry from Merrimack College.
Nexo Therapeutics
Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies. Nexo combines covalent ligand discovery and chemical biology with expertise in cancer biology and medicinal chemistry to target fundamental drivers of cancer by innovative approaches. With facilities in Golden, CO and Watertown, MA, Nexo is led by Founder and CEO, Andrew Phillips, PhD. For more information, please visit www.nexotx.com.